Clinical Trial Update: A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pharmacokinetics, efficacy, and safety of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab with chemotherapy in Chin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Perjeta (pertuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: HER2-positive Early Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-02-16